What is LUNAR?
Project LUNAR is an ambitious effort to study how well Guardant Health’s technology can detect early stage cancer. Sample collection is underway from multiple trial sites, with data expected in early 2017.
We want to bend cancer mortality curves by detecting cancer early, when the opportunity to treat and cure is greatest
Why Guardant Health?
Guardant Health is a pioneer in non-invasive cancer
diagnostics, and the first company to commercialize a
comprehensive genomic liquid biopsy. Our technology has been ordered by thousands of oncologists for tens of
thousands of advanced cancer patients.
These brave patients have helped us map the landscape of critical cancer-causing mutations, and given us a greater understanding of how tumors evolve.
This knowledge has enabled us to iteratively push the performance limits of our technology to develop an affordable LUNAR assay that can detect a single mutated DNA fragment among hundreds of thousands of genome copies.